The study enrolled 19 patients and was planned to evaluate the ORR of TVB-2640 in combination with paclitaxel and trastuzumab in patients with paclitaxel- and trastuzumab-resistant advanced HER2-positive breast cancer, and changes in FASN, phosphorylated (p)AKT, and pS6 expression in the tumor tissues after the first cycle of the treatment. This evidence concerns the gene ERBB2 and breast carcinoma.